Primary application of mean apparent propagator-MRI diffusion model in the grading of diffuse glioma

Peng Wang1, Lixin Weng2, Shenghui Xie1

  • 1Department of Radiology, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, 010059, China.

Abstract

Insights

Mean apparent propagator-magnetic resonance imaging (MAP-MRI) effectively distinguishes diffuse glioma grades II and III, and II and IV, aiding preoperative diagnosis. However, it cannot differentiate between grade III and IV gliomas.

Area of Science:

  • Neuroimaging
  • Oncology
  • Radiology

Background:

  • Diffuse gliomas are primary brain tumors with varying grades impacting prognosis.
  • Accurate preoperative grading is crucial for treatment planning.
  • Current grading methods can be invasive or lack specificity.

Purpose of the Study:

  • To assess the diagnostic performance of mean apparent propagator-magnetic resonance imaging (MAP-MRI) in differentiating diffuse glioma grades.
  • To evaluate specific MAP-MRI parameters for their ability to distinguish between glioma grades II, III, and IV.

Main Methods:

  • Thirty-six patients with pathologically confirmed diffuse gliomas underwent MAP-MRI.
  • Key MAP-MRI parameters including non-Gaussianity (NG) and return to origin probability (RTOP) were measured.
  • Statistical analysis and receiver operating characteristic (ROC) curves were used to determine diagnostic value.

Main Results:

  • MAP-MRI parameters like NG, NGAx, and NGRad showed significant differences between grade II and III gliomas (AUC > 0.82).
  • Distinctions were also observed between grade II and IV gliomas for parameters including NG, NGAx, NGRad, RTAP, and RTOP (AUC > 0.76).
  • MAP-MRI could not reliably differentiate between grade III and IV gliomas.

Conclusions:

  • Quantitative MAP-MRI parameters show promise in noninvasively distinguishing between lower-grade gliomas (II vs. III, II vs. IV) preoperatively.
  • These findings suggest clinical utility for MAP-MRI in guiding tumor pathological grading.
  • Further research may be needed to improve differentiation between higher-grade gliomas (III vs. IV).